Abstract
Pleural mesothelioma (PM) remains an incurable cancer with few effective therapeutic options and limited understanding of its targetable dependencies, owing in part to a scarcity of clinically relevant, scalable models. Here, we describe establishment of an annotated biobank of 26 patient-derived PM organoids that faithfully recapitulate the clinical, genomic and histopathological landscapes of their parent tumours, including driver mutations, copy-number alterations and mutational signatures. By integrating these organoid models with a complementary collection of low-passage primary PM cell lines, we generate a functional precision oncology platform for PM. Genome-scale CRISPR-Cas9 screening across 23 patient-derived PM models uncovered 1,150 core fitness genes, including 638 not shared with pan-cancer core essentials, highlighting critical requirements for proteostasis, DNA repair, RNA processing and cell-cycle control. Parallel profiling of 106 compounds across 36 PM models revealed broad therapeutic vulnerabilities in proteostasis, growth signalling and epigenetic regulation. Beyond these shared vulnerabilities, both screens uncovered genotype-specific dependencies and drug responses linked to recurrent PM alterations. This functional map of shared and genotype-specific dependencies establishes patient-derived organoids as a scalable platform for precision therapeutic discovery in pleural mesothelioma
Funding Information
  • British Lung Foundation (ABR 12-1)
  • Asthma + Lung UK (MKMRFPG18-3)
  • Asthma + Lung UK (MPG24\11)
  • June Hancock Mesothelioma Research Fund (NA)
  • Wellcome Trust (206194)
  • Wellcome Trust (220540/Z/20/A)
  • NIHR Cambridge Biomedical Research Centre (NIHR203312)
  • Cancer Research UK Cambridge Center (CTRQQR-2021\100012)